Given the strong activation of NFAT-signaling in NRVCM, C2C12 and HEK cells, and the upregulation of SUMO2 in mouse models of cardiac hypertrophy as well as in human patients suffering from DCM or ICM, we investigated the potential phenotypic and molecular effects of SUMO2 in NRVCM. This evidence concerns the gene SUMO2 and familial dilated cardiomyopathy.